Taiwan lipid guidelines for high risk patients. In Taiwan, the prevalence of hyperlipidemia increased due to lifestyle and dietary habit changes. Low density lipoprotein cholesterol (LDL- C) and non- high density lipoprotein cholesterol (non- HDL- C) are all significant predicting factors of coronary artery disease in Taiwan. We recognized that lipid control is especially important in patients with existed atherosclerotic cardiovascular diseases (ASCVD), including coronary artery disease (CAD), ischemic stroke and peripheral arterial disease (PAD).
Because the risk of ASCVD is high in patients with diabetes mellitus (DM), chronic kidney disease (CKD) and familial hypercholesterolemia (FH), lipid control is also necessary in these patients. Lifestyle modification is the first step to control lipid. Weight reduction, regular physical exercise and limitation of alcohol intake all reduce triglyceride (TG) levels.
Lipid- lowering drugs include HMG- Co. A reductase inhibitors (statins), cholesterol absorption inhibitors (ezetimibe), proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, nicotinic acids (niacin), fibric acids derivatives (fibrates), and long- chain omega- 3 fatty acids. Statin is usually the first line therapy. Combination therapy with statin and other lipid- lowering agents may be considered in some clinical settings.
For patients with acute coronary syndrome (ACS) and stable CAD, LDL- C < 7. L is the major target. A lower target of LDL- C < 5. L can be considered in ACS patients with DM. After treating LDL- C to target, non- HDL- C can be considered as a secondary target for patients with TG . The suggested non- HDL- C target is < 1.
The world’s leading source of in-depth news and analysis on risk management, derivatives and regulation.
L in ACS and CAD patients. For patients with ischemic stroke or transient ischemic attack presumed to be of atherosclerotic origin, statin therapy is beneficial and LDL- C < 1. L is the suggested target. For patients with symptomatic carotid stenosis or intracranial arterial stenosis, in addition to antiplatelets and blood pressure control, LDL- C should be lowered to < 1. L. Statin is necessary for DM patients with CV disease and the LDL- C target is < 7. L. For diabetic patients who are .
- The guideline recommendations were generated after reviewing international randomized clinical trials that are relevant to the above-mentioned high-risk patient groups.
- Research Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data BMJ 2017; 357 doi: https://doi.org/10.
- Original Article. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. Rolnik, M.D., David Wright, Ph.D., Liona C. Poon, M.D., Neil.
- With unmatched integrity and professionalism, Pensions & Investments consistently delivers news, research and analysis to the executives who manage the flow of funds.
After achieving LDL- C target, combination of other lipid- lowering agents with statin is reasonable to attain TG < 1. L and HDL- C > 4. L in women in DM. LDL- C increased CV risk in patients with CKD. In adults with glomerular filtration rate (GFR) < 6.
Wise Driver Care 2.1.814 Free to download and update outdated Windows devices drivers Last updated: 2017-08-16 Size: 7.37 MB. The 2017 Gartner Security & Risk Management Summit covers technology research, information security and enterprise risk management strategies. Learn more!
L/min/1. 7. 3m. 2 without chronic dialysis (CKD stage 3–5), statin therapy should be initiated if LDL- C . Ezetimibe can be added to statin to consolidate the CV protection in CKD patients. Open Water 3 (2017) The Movie High Quality. Mutations in LDL receptor, apolipoprotein B and PCSK9 genes are the common causes of FH. Diagnosis of FH usually depends on family history, clinical history of premature CAD, physical findings of xanthoma or corneal arcus and high levels of LDL- C. In addition to conventional lipid lowering therapies, adjunctive treatment with mipomersen, lomitapide, or PCSK9 inhibitors become necessary to further reduce LDL- C in patients with FH. Overall, these recommendations are to help the health care professionals in Taiwan to treat hyperlipidemia with current scientific evidences. We hope the prescription rate of lipid lowering drugs and control rate of hyperlipidemia in high risk patients could be increased by implementation of the clinical guidelines.
The major purpose is to improve clinical outcomes of these high risk patients through the control of hyperlipidemia.